Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply

Affiliations

¹ Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
² University Hospital Gasthuisberg, Leuven, Belgium.
³ Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
⁴ Takeda Development Centre Europe Ltd, London, UK.
⁵ Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Editorial

U Mahadevan et al. Aliment Pharmacol Ther. 2017 May.

. 2017 May;45(9):1284.

doi: 10.1111/apt.14054.

¹ Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
² University Hospital Gasthuisberg, Leuven, Belgium.
³ Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
⁴ Takeda Development Centre Europe Ltd, London, UK.
⁵ Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

No abstract available

Comment on

Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Mahadevan U, et al. Aliment Pharmacol Ther. 2017 Apr;45(7):941-950. doi: 10.1111/apt.13960. Epub 2017 Feb 7. Aliment Pharmacol Ther. 2017. PMID: 28169436
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
Shim HH, Seow CH. Shim HH, et al. Aliment Pharmacol Ther. 2017 May;45(9):1283-1284. doi: 10.1111/apt.14027. Aliment Pharmacol Ther. 2017. PMID: 28370049 No abstract available.